Evaluation of Hyperbilirubinemia
The evaluation of hyperbilirubinemia must begin with fractionating bilirubin into conjugated (direct) and unconjugated (indirect) components, as this single step determines the entire diagnostic pathway and differentiates benign conditions from life-threatening disease.
Initial Laboratory Assessment
The first-line workup requires:
- Total and fractionated bilirubin (conjugated vs. unconjugated) 1, 2
- Complete blood count (to assess for hemolysis)
- Aspartate transaminase (AST) and alanine transaminase (ALT)
- Alkaline phosphatase (ALP)
- Gamma-glutamyltransferase (GGT)
- Albumin
- Prothrombin time/INR 2
Critical Distinction: Direct vs. Conjugated Bilirubin
Understanding that "direct" and "conjugated" bilirubin are not interchangeable is essential. Direct bilirubin includes both conjugated bilirubin and delta bilirubin (albumin-bound with a 21-day half-life), which explains why direct hyperbilirubinemia persists longer 1. If prolonged hyperbilirubinemia remains unexplained, request breakdown of direct bilirubin into conjugated and delta fractions 1.
Algorithmic Approach Based on Bilirubin Fractionation
Unconjugated (Indirect) Hyperbilirubinemia
When conjugated bilirubin is <20-30% of total bilirubin, consider:
Gilbert Syndrome (5-10% of population):
Hemolysis:
Crigler-Najjar syndrome (rare, severe UGT1A1 deficiency) 5
Conjugated (Direct) Hyperbilirubinemia
When direct bilirubin is >35% of total bilirubin or conjugated bilirubin >1.0 mg/dL (if TSB ≤5 mg/dL), this indicates hepatocellular or cholestatic disease 1, 4, 1, 4.
Immediate imaging is mandatory:
Ultrasound abdomen as first-line imaging:
CT abdomen with IV contrast if:
- US inconclusive for obstruction etiology
- Malignancy suspected (sensitivity 95%, specificity 93% for biliary strictures) 6
MRCP when:
Specific Clinical Contexts
Drug-Induced Liver Injury (DILI)
Persistent isolated elevations of direct bilirubin in patients with underlying liver disease warrant close monitoring as potential DILI, especially with synthetic dysfunction 1. When DILI suspected, direct bilirubin fraction is usually >35% 1.
Critical pitfall: Isolated total bilirubin elevation without transaminase elevation should NOT be labeled DILI, even if predominantly direct hyperbilirubinemia 1.
Additional Workup for Conjugated Hyperbilirubinemia
- Viral hepatitis serologies (HAV, HBV, HCV, HEV, EBV) 6
- Autoimmune markers if indicated (ANA, ASMA, ANCA) 8
- Iron studies (hemochromatosis)
- Ceruloplasmin (Wilson disease in younger patients)
- Alpha-1 antitrypsin level
Coagulation Abnormalities
If INR is prolonged:
- Repeat within 2-5 days to confirm and assess trajectory 1
- Administer parenteral vitamin K before attributing to liver disease, as cholestatic patients are at risk for fat-soluble vitamin deficiencies 1
- Exception: Skip vitamin K trial if immediate liver transplantation evaluation needed 1
Hepatitis B Reactivation
In patients with isolated hepatitis B core antibody positivity (especially on immunosuppression), obtain HBV DNA when liver tests suddenly elevate to exclude reactivation 1.
When Liver Biopsy is Indicated
Consider liver biopsy when:
- Etiology remains unclear after comprehensive laboratory and imaging evaluation 2
- Steroid-refractory hepatitis 8
- Need to differentiate vanishing bile duct syndrome from primary biliary cholangitis 1
- Establishing prognosis and management in unclear cases 2
Common Pitfalls to Avoid
- Do not assume direct = conjugated bilirubin—request fractionation if prolonged hyperbilirubinemia persists 1
- Do not diagnose Gilbert syndrome without confirming conjugated fraction <20-30% and excluding hemolysis 1
- Do not obtain venous sample to "confirm" elevated capillary bilirubin—this delays treatment without added value 4
- Do not attribute prolonged INR to liver disease before vitamin K trial 1
- Do not miss G6PD deficiency—levels may be falsely normal during active hemolysis 4